ReviewMovement disorders : official journal of the Movement Disorder Society2017
Aging and Parkinson's disease: Different sides of the same coin?
Review in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.Journal of comparative effectiveness research · 2025Pooled it
- Association between the risk and severity of Parkinson's disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2023Pooled it
- Impact of aging on animal models of Parkinson's disease.Frontiers in aging neuroscience · 2022Pooled it
- Metallothionein and neurodegenerative diseases.Neural regeneration research · 2026Article
- DYRK1A and Parkinson's disease, facts and hypotheses.Neurobiology of disease · 2026Review
- Parkinson's disease subtypes and their relationship to dementia with Lewy bodies: a comparative neuroimaging analysis based on nigrostriatal degeneration.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Single-nucleus multiomic profiling of the aging mouse substantia nigra reveals conserved gene alterations linked to Parkinson's disease.Genome research · 2026Article
- Unraveling Parkinson's disease: The mystery of mitochondria and the role of aging.Genes & diseases · 2026Review
- Novel insights into relationships between metabolic covariance patterns of FDG-PET data and clinical status in Parkinson's disease using partial least squares correlation analysis.Journal of Parkinson's disease · 2026Article
- Epidemiology of Parkinson's disease - Global burden of disease research from 1990 to 2021 and future trend predictions.Clinical parkinsonism & related disorders · 2026Review
- Neurodegeneration in Parkinson's Disease: The Role of Environmental Toxins.Journal of central nervous system disease · 2026Review
- Article
- Exploring the Therapeutic Potential of Plant-Based Natural Products in Combating Aging.Current drug targets · 2026Review
- Social Determinants of Health and Their Association With Parkinson's Disease Prevalence in US Adults: Insights From NHANES 2001-2020.Behavioural neurology · 2026Article
- Article
- Body mass index, metabolically abnormal status, and incident Parkinson's disease: Data from the UK Biobank.Journal of Parkinson's disease · 2025Article
- Article
- Article
- Genetics Influences Telomere Length in Parkinson's Disease: A Study in Monozygotic Discordant Twins.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Advancing age and sex modulate antidyskinetic efficacy of striatal CaNeurobiology of aging · 2025Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite abundant epidemiological evidence in support of aging as the primary risk factor for PD, biological correlates of a connection have been elusive. In this article, we address the following question: does aging represent biology accurately characterized as pre-PD? We present evidence from our work on midbrain dopamine neurons of aging nonhuman primates that demonstrates that markers of known correlates of dopamine neuron degeneration in PD, including impaired proteasome/lysosome function, oxidative/nitrative damage, and inflammation, all increase with advancing age and are exaggerated in the ventral tier substantia nigra dopamine neurons most vulnerable to degeneration in PD. Our findings support the view that aging-related changes in the dopamine system approach the biological threshold for parkinsonism, actively producing a vulnerable pre-parkinsonian state. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.